681679-M

Iron Chelator IV, 21H7

The Iron Chelator IV, 21H7 controls the biological activity of iron-regulated enzymes. This small molecule/inhibitor is primarily used for Cancer applications.

• Sinonimo/i: Iron Chelator IV, 21H7, 6-Bromo-Nʹ-(2-hydroxybenzylidene)-2-methylquinoline-4-carbohydrazide
• Formula empirica (notazione di Hill): C₁₈H₁₄BrN₃O₂
• Peso molecolare: 384.23
• Codice UNSPSC: 12352200

Proprietà

• Livello qualitativo: 100
• Saggio: ≥97% (HPLC)
• Forma fisica: solid
• Produttore/marchio commerciale: Calbiochem^®
• Condizioni di stoccaggio: OK to freeze; protect from light
• Colore: off-white
• Solubilità: DMSO: 5 mg/mL, light yellow
• Temperatura di conservazione: 2-8°C

Descrizione

Descrizione generale

A cell-permeable salicylaldehyde-acylhydrazone iron chelator that is 20-times more efficient than DFO/desferrioxamine (Cat. No. 252750) in depleting intracellular iron in colon cancer SW480 cells. Iron chelators exert their biological activities by affecting iron-regulated enzymes and singaling events, including HIF1α transcription activation (Effective [21H7] = 10 µM in SW480 and DLD-1 cells) due to inhibition of PHD- (prolyl hydroxylase) mediated HIF1α degradation, as well as stalling and enhancing, respectively, Ferritin and TfRI (Transferrin Receptor I) mRNA translation (Effective [21H7] = 10 µM in SW480 cells) due to iron depletion-induced IRP (Iron Regulatory Protein) IREs (Iron Response Elements) binding. Iron depletion is also reported to inhibit the growths of colorectal adenocarcinoma cultures, DLD-1 (IC₅₀ = 0.6 and 2.9 µM, respectively, by 21H7 and DFO) and SW480 (IC₅₀ = 1.0 and 3.8 µM, respectively, by 21H7 and DFO), as a result of Wnt signaling pathway blockage (Effective conc. = 5 µM 21H7 or 100 µM DFO).

A cell-permeable salicylaldehyde-acylhydrazone iron chelator that is 20-times more efficient than DFO/desferrioxamine (Cat. No. 252750) in depleting intracellular iron in colon cancer SW480 cells. Iron chelators exert their biological activities by affecting iron-regulated enzymes and singaling events, including HIF1α transcription activation due to inhibition of PHD- (prolyl hydroxylase) mediated HIF1α degradation, as well as altered mRNA translations due to enhanced IRP (Iron Regulatory Protein) IREs (Iron Response Elements) binding. Cellular iron depletion is also reported to inhibit the growths of colorectal adenocarcinoma cultures, DLD-1 (IC₅₀ = 0.6 and 2.9 µM, respectively, by 21H7 and DFO) and SW480 (IC₅₀ = 1.0 and 3.8 µM, respectively, by 21H7 and DFO), as a result of Wnt signaling pathway blockage (Effective conc. = 5 µM 21H7 or 100 µM DFO).

Attenzione

Toxicity: Standard Handling (A)

Nota sulla preparazione

Slight warming (45°C) is required for complete solubilization.

Altre note

Song, S., et al. 2011. Cancer Res.71, 7628.

Note legali

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informazioni sulla sicurezza

• Codice della classe di stoccaggio: 11 - Combustible Solids
• Classe di pericolosità dell'acqua (WGK): WGK 3
• Punto d’infiammabilità (°F): Not applicable
• Punto d’infiammabilità (°C): Not applicable